Cargando…

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

BACKGROUND: Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients treated with interferon β (IFNβ) develop ADA, for which a genetic predisposition exists. Here, we present a genome-wide asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andlauer, Till F. M., Link, Jenny, Martin, Dorothea, Ryner, Malin, Hermanrud, Christina, Grummel, Verena, Auer, Michael, Hegen, Harald, Aly, Lilian, Gasperi, Christiane, Knier, Benjamin, Müller-Myhsok, Bertram, Jensen, Poul Erik Hyldgaard, Sellebjerg, Finn, Kockum, Ingrid, Olsson, Tomas, Pallardy, Marc, Spindeldreher, Sebastian, Deisenhammer, Florian, Fogdell-Hahn, Anna, Hemmer, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641861/ https://www.ncbi.nlm.nih.gov/pubmed/33143745 http://dx.doi.org/10.1186/s12916-020-01769-6

Ejemplares similares

Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
por: Link, Jenny, et al.
Publicado: (2014)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
por: Bachelet, Delphine, et al.
Publicado: (2016)

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta
por: Ingenhoven, Kathleen, et al.
Publicado: (2017)

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
por: Link, Jenny, et al.
Publicado: (2017)

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
por: Kharlamova, Nastya, et al.
Publicado: (2020)

The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review
por: Hegen, Harald, et al.
Publicado: (2019)

A Genetic Association Test Accounting for Skewed X-Inactivation With Application to Biotherapy Immunogenicity in Patients With Autoimmune Diseases
por: Hässler, Signe, et al.
Publicado: (2022)

Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis
por: Auer, Michael, et al.
Publicado: (2018)

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium
por: Hässler, Signe, et al.
Publicado: (2020)

GWAS meta-analysis followed by Mendelian randomization revealed potential control mechanisms for circulating α-Klotho levels
por: Gergei, Ingrid, et al.
Publicado: (2021)

Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi
por: Berek, Klaus, et al.
Publicado: (2020)

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis
por: Noll, Christina, et al.
Publicado: (2022)

Smoking is not associated with higher prevalence of JC virus in MS patients
por: Auer, Michael, et al.
Publicado: (2018)

SARS-CoV2 infection as a potential trigger for severe relapse in a patient with multiple sclerosis who stopped disease modifying treatment due to COVID-19 pandemic
por: Auer, Michael, et al.
Publicado: (2021)

CSF parameters associated with early MRI activity in patients with MS
por: Klein, Ana, et al.
Publicado: (2019)

A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort
por: Duhazé, Julianne, et al.
Publicado: (2020)

The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis
por: Cirac, Ana, et al.
Publicado: (2021)

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity
por: Hegen, Harald, et al.
Publicado: (2022)

Assessing the effect of genetic markers on drug immunogenicity from a mechanistic model-based approach
por: Duhazé, Julianne, et al.
Publicado: (2020)

Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study
por: Auer, Michael, et al.
Publicado: (2019)

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study
por: Hegen, Harald, et al.
Publicado: (2017)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study
por: Berek, Klaus, et al.
Publicado: (2021)

HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis
por: Hoffmann, Steve, et al.
Publicado: (2008)

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study
por: Bsteh, Gabriel, et al.
Publicado: (2016)

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
por: Hegen, Harald, et al.
Publicado: (2018)

Influence of physical activity on serum vitamin D levels in people with multiple sclerosis
por: Bauer, Angelika, et al.
Publicado: (2020)

Cerebrospinal fluid protein in Guillain–Barré syndrome: Need for age‐dependent interpretation
por: Hegen, Harald, et al.
Publicado: (2020)

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
por: Auer, Michael, et al.
Publicado: (2021)

Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
por: Auer, Michael, et al.
Publicado: (2022)

Gene Expression in Spontaneous Experimental Autoimmune Encephalomyelitis Is Linked to Human Multiple Sclerosis Risk Genes
por: Faber, Hans, et al.
Publicado: (2020)

Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
por: Persson Berg, Linn, et al.
Publicado: (2022)

Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study
por: Wurth, Sebastian, et al.
Publicado: (2017)

Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study
por: Bsteh, Gabriel, et al.
Publicado: (2017)

JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants
por: Sundqvist, Emilie, et al.
Publicado: (2014)

Integrated PTR-ToF-MS, GWAS and biological pathway analyses reveal the contribution of cow’s genome to cheese volatilome
por: Pegolo, Sara, et al.
Publicado: (2018)

Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1qriqvg3k8ru7kknl23dtv2ijr